ABBVAbbVieSigning up patients
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer · c-MET
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 490 (planned)
- Started
- Dec 10, 2025
- Main results expected
- Sep 2030
- Fully finished
- Sep 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2: Objective Response (OR) Assessed by the Blinded Independent Central Review (BICR)
Measured over: Up to Approximately 69 Months
Phase 3: Progression-Free Survival (PFS) as assessed by the BICR
Measured over: Up to Approximately 69 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07155187 · record last updated 2026-10-05 · checked 2026-11-09 15:47 UTC